Highest-materiality recent filing
ENvue Medical amends CEO equity plan, appoints David Johnson as Chairman with 3.5% RSU grant
Amendment changes CEO Doron Besser's equity grants from annual to quarterly, with prorated gross-up on termination without cause.
ENvue Medical removes Series H Preferred Floor Price in exchange for $2.5M investment
Entered Amendment Agreement with Required Holders to file Certificate of Amendment removing Floor Price from Series H Convertible Preferred Stock.
ENvue Medical amends 2024 Long Term Incentive Plan for Israeli tax compliance and name change
Board approved amended and restated 2024 Long Term Incentive Plan on December 24, 2025.
NanoVibronix amends CEO contract with 9% equity grant; appoints interim CFO
CEO Doron Besser new base salary $360K, bonus up to $180K; severance of 12 months' base salary on change-of-control termination.
NanoVibronix changes name to ENvue Medical, ticker to FEED effective Dec 12, 2025
Effective Dec 12, 2025, NanoVibronix changed name to ENvue Medical, Inc. and ticker symbol from NAOV to FEED on Nasdaq.
Christopher Fashek, Thomas Mika, Martin Goldstein, Brian Murphy retired immediately before the 2025 Annual Meeting for personal reasons; no disagreement with Company.
NanoVibronix to rebrand as ENvue Medical, focus on enteral-feeding navigation platform
ENvue feeding-tube placement system identified as core growth platform; 38 hospitals already using it.
NanoVibronix announces four directors will not stand for reelection at 2025 annual meeting
Christopher Fashek, Thomas Mika, Martin Goldstein, and Brian Murphy to retire from Board immediately prior to 2025 Annual Meeting.
NanoVibronix prices $2M registered direct offering of common stock and prefunded warrants at $7.01
Offering of 74,114 common shares and prefunded warrants for 217,090 shares at $7.01 per share (or $7.009 per warrant).
NanoVibronix dismisses Zwick CPA, appoints E&Y as auditor; CFO Brown gets amended deal
Dismissed Zwick CPA PLLC; new auditor is Kost Forer Gabbay & Kasierer (E&Y) for FY2025.
NanoVibronix effects 1-for-10 reverse stock split effective Aug 11, 2025
Reverse stock split reduces outstanding shares from 7,968,868 to ~796,887.
NanoVibronix appoints Rita Silberberg as EVP Finance, CAO and Corporate Secretary
Appointment effective July 24, 2025; Silberberg also named Corporate Secretary same day.
NanoVibronix raises $8M in private placement of Series H convertible preferred and warrants
Initial closing of $8M gross proceeds: 8,889 Series H preferred shares ($1,000 stated value, convertible at $1.01/sh) and warrants for 4,678,363 shares at $2.25/sh.
NanoVibronix shareholders approve reverse stock split with 1:2 to 1:50 range
Reverse stock split amendment approved: ratio of 1-for-2 to 1-for-50, at Board discretion, within one year.
NanoVibronix special meeting adjourned due to lack of quorum; reconvened July 17
Special Meeting opened and adjourned without any business due to absence of quorum.
NanoVibronix corrects typo in Series G preferred stock Floor Price to $1.91
Corrected definition of Floor Price from $1.02 to $1.91 in Series G Preferred Stock Certificate of Designation.
NanoVibronix appoints Doron Besser as CEO; Brian Murphy retires but stays on board
Brian Murphy retired as CEO of NanoVibronix effective June 4, 2025, and will remain as a director.
NanoVibronix raises $10M in public offering of Series G preferred and warrants
Gross proceeds ~$10M from 400,000 Series G convertible preferred shares at $25/share, each with a warrant to buy 4.9M common shares at $2.04.
the Board of Directors (the “ Board ”) of NanoVibronix, Inc. (the “ Company ”) appointed Doron Besser, M.D., a director of the Board and Chief Executive Officer and President of the Company’s wholly-owned subsidiary, ENvue Medical Holdings LLC (“ ENvue ”), as the Company’s Chief Executive Officer (“ CEO ”), effective as of the same date
Brian Murphy resigned from the Company as its CEO due to Mr. Murphy’s retirement, effective as of the same date.
Max materiality 0.75 · Median 0.57 · Most common event other_material